Hem/Onc Roundup: Weight Loss Drug Pulled From Shelves after Cancer Link, Mortality in Cancer Survivors, and more

Here are the top stories covered by DocWire News this week in the Hematology & Oncology section. This week, a study indicated the top 10 states with the highest risk for ultraviolet (UV)-linked melanoma, younger patients with colon cancer have a higher mortality risk, and more.

The Food and Drug Administration requested that weight loss drug lorcaserin (Belviq) be withdrawn from the shelves after clinical trial data suggested that it increased the risk of cancer. Belviq’s manufacturer Eisai requested to voluntarily withdraw the drug.

A new report highlighted the top 10 states with the highest risk for UV-linked melanoma, with Utah being number one. The results were published in the International Journal of Cancer.

A new study compared mortality among pediatric and adult colon cancer patients. The researchers concluded that pediatric and young adult patients have poorer three- and five-year stage-for-stage overall survival and recurrence free survival rates.

Young adult cancer survivors have an increased risk for mortality and severe and life-threatening chronic conditions compared with the general population, according to a study published in The Lancet Oncology.

In case you missed it, more hem/onc headlines are featured below: